Loading…

Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC)

[Display omitted] Lipid nanoparticles are well-known nanocarriers for improved drug delivery. Their formulation development typically involves three formulations steps. In the first part a suitable lipid mixture which enables a high loading capacity and high encapsulation efficacy of the active need...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2020-02, Vol.576, p.118918-118918, Article 118918
Main Authors: Kovačević, Anđelka B., Müller, Rainer H., Keck, Cornelia M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c483t-93df9a7e3f12f7511aa7086f31df03a5312eefa24e2501d5b23644a592f15bb93
cites cdi_FETCH-LOGICAL-c483t-93df9a7e3f12f7511aa7086f31df03a5312eefa24e2501d5b23644a592f15bb93
container_end_page 118918
container_issue
container_start_page 118918
container_title International journal of pharmaceutics
container_volume 576
creator Kovačević, Anđelka B.
Müller, Rainer H.
Keck, Cornelia M.
description [Display omitted] Lipid nanoparticles are well-known nanocarriers for improved drug delivery. Their formulation development typically involves three formulations steps. In the first part a suitable lipid mixture which enables a high loading capacity and high encapsulation efficacy of the active needs to be identified (lipid screening). In the second step suitable stabilizers that enable the production of small-sized lipid nanoparticles with narrow size distribution and sufficient physical stability need to be identified (stabilizer screening, optimization of production parameters) and in the third step the biopharmaceutical efficacy needs to be evaluated. Based on the results obtained the formulations will require further optimization. The classical formulation development of lipid nanoparticles and especially the classical lipid screening is tedious. Therefore, in this study, a novel approach for the lipid screening that was based on the determination of the Hansen solubility parameters was evaluated and the results obtained were compared to the results from the classical model. Tacrolimus was used as a model drug. Results showed that both lipid screenings led to similar results, indicating that the new approach can be used for future developments. The optimized formulation was composed of a lipid matrix system that contained waxes, triglycerides and monoacylglycerols with various carbon chain lengths (C8, C10, C16, C18) and enabled an encapsulation efficiency of ~99%. The stabilizer screening showed that surfactants with high HLB values, lower molecular weight, and shorter alkyl chain length tended to form smaller particles with narrower size distribution and better physical stability. The most suitable surfactant was found to be a caprylyl/capryl glucoside (Plantacare® 810), a PEG-free stabilizer, that is extremely mild for atopic skin. It led to particle sizes of about 200 nm and a zeta potential well above |30| mV. The optimized formulation contained 0.1% tacrolimus and possessed good physical stability. In conclusion, an optimized method for the selection of lipids that results in a limited number of experiments could be established and tacrolimus loaded lipid nanoparticles with similar drug load as a marketed formulation was successfully developed in this study.
doi_str_mv 10.1016/j.ijpharm.2019.118918
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2330331385</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517319309639</els_id><sourcerecordid>2330331385</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-93df9a7e3f12f7511aa7086f31df03a5312eefa24e2501d5b23644a592f15bb93</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EokvhI4ByLIdsPZk4f7ggtKJQaUUv5Wx57TF45djBTlbiY_CNSZWlBy49zWF-80bvPcbeAt8Ch-b6uHXH8adKw7bi0G8Buh66Z2wDXYsl1m3znG04tl0poMUL9irnI-e8qQBfsgtcKN6LesP-3MQ0zF5NLobC0Il8HAcKUxFt4d3oTBFUiKNKk9Oe8ofidhhTPJE5b7NORMGFH4UK5n-BSekUvRvmXPioDK1ieUqznub0qKFVSo5SLq6-7XfvX7MXVvlMb87zkn2_-Xy_-1ru777c7j7tS113OJU9GturltBCZVsBoFTLu8YiGMtRCYSKyKqqpkpwMOJQYVPXSvSVBXE49HjJrlbdxc-vmfIkB5c1ea8CxTnLCpEjAnZiQcWKLnZyTmTlmNyg0m8JXD60IY_y3IZ8aEOubSx3784v5sNA5vHqX_wL8HEFaDF6WjKQWTsKmoxLpCdponvixV_946Ew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2330331385</pqid></control><display><type>article</type><title>Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC)</title><source>ScienceDirect Freedom Collection</source><creator>Kovačević, Anđelka B. ; Müller, Rainer H. ; Keck, Cornelia M.</creator><creatorcontrib>Kovačević, Anđelka B. ; Müller, Rainer H. ; Keck, Cornelia M.</creatorcontrib><description>[Display omitted] Lipid nanoparticles are well-known nanocarriers for improved drug delivery. Their formulation development typically involves three formulations steps. In the first part a suitable lipid mixture which enables a high loading capacity and high encapsulation efficacy of the active needs to be identified (lipid screening). In the second step suitable stabilizers that enable the production of small-sized lipid nanoparticles with narrow size distribution and sufficient physical stability need to be identified (stabilizer screening, optimization of production parameters) and in the third step the biopharmaceutical efficacy needs to be evaluated. Based on the results obtained the formulations will require further optimization. The classical formulation development of lipid nanoparticles and especially the classical lipid screening is tedious. Therefore, in this study, a novel approach for the lipid screening that was based on the determination of the Hansen solubility parameters was evaluated and the results obtained were compared to the results from the classical model. Tacrolimus was used as a model drug. Results showed that both lipid screenings led to similar results, indicating that the new approach can be used for future developments. The optimized formulation was composed of a lipid matrix system that contained waxes, triglycerides and monoacylglycerols with various carbon chain lengths (C8, C10, C16, C18) and enabled an encapsulation efficiency of ~99%. The stabilizer screening showed that surfactants with high HLB values, lower molecular weight, and shorter alkyl chain length tended to form smaller particles with narrower size distribution and better physical stability. The most suitable surfactant was found to be a caprylyl/capryl glucoside (Plantacare® 810), a PEG-free stabilizer, that is extremely mild for atopic skin. It led to particle sizes of about 200 nm and a zeta potential well above |30| mV. The optimized formulation contained 0.1% tacrolimus and possessed good physical stability. In conclusion, an optimized method for the selection of lipids that results in a limited number of experiments could be established and tacrolimus loaded lipid nanoparticles with similar drug load as a marketed formulation was successfully developed in this study.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2019.118918</identifier><identifier>PMID: 31870954</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Hansen solubility parameter ; Particle size ; Polyhydroxy surfactant ; Tacrolimus ; Tailor-made lipid nanoparticle</subject><ispartof>International journal of pharmaceutics, 2020-02, Vol.576, p.118918-118918, Article 118918</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-93df9a7e3f12f7511aa7086f31df03a5312eefa24e2501d5b23644a592f15bb93</citedby><cites>FETCH-LOGICAL-c483t-93df9a7e3f12f7511aa7086f31df03a5312eefa24e2501d5b23644a592f15bb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31870954$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kovačević, Anđelka B.</creatorcontrib><creatorcontrib>Müller, Rainer H.</creatorcontrib><creatorcontrib>Keck, Cornelia M.</creatorcontrib><title>Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC)</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted] Lipid nanoparticles are well-known nanocarriers for improved drug delivery. Their formulation development typically involves three formulations steps. In the first part a suitable lipid mixture which enables a high loading capacity and high encapsulation efficacy of the active needs to be identified (lipid screening). In the second step suitable stabilizers that enable the production of small-sized lipid nanoparticles with narrow size distribution and sufficient physical stability need to be identified (stabilizer screening, optimization of production parameters) and in the third step the biopharmaceutical efficacy needs to be evaluated. Based on the results obtained the formulations will require further optimization. The classical formulation development of lipid nanoparticles and especially the classical lipid screening is tedious. Therefore, in this study, a novel approach for the lipid screening that was based on the determination of the Hansen solubility parameters was evaluated and the results obtained were compared to the results from the classical model. Tacrolimus was used as a model drug. Results showed that both lipid screenings led to similar results, indicating that the new approach can be used for future developments. The optimized formulation was composed of a lipid matrix system that contained waxes, triglycerides and monoacylglycerols with various carbon chain lengths (C8, C10, C16, C18) and enabled an encapsulation efficiency of ~99%. The stabilizer screening showed that surfactants with high HLB values, lower molecular weight, and shorter alkyl chain length tended to form smaller particles with narrower size distribution and better physical stability. The most suitable surfactant was found to be a caprylyl/capryl glucoside (Plantacare® 810), a PEG-free stabilizer, that is extremely mild for atopic skin. It led to particle sizes of about 200 nm and a zeta potential well above |30| mV. The optimized formulation contained 0.1% tacrolimus and possessed good physical stability. In conclusion, an optimized method for the selection of lipids that results in a limited number of experiments could be established and tacrolimus loaded lipid nanoparticles with similar drug load as a marketed formulation was successfully developed in this study.</description><subject>Hansen solubility parameter</subject><subject>Particle size</subject><subject>Polyhydroxy surfactant</subject><subject>Tacrolimus</subject><subject>Tailor-made lipid nanoparticle</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkU9v1DAQxS0EokvhI4ByLIdsPZk4f7ggtKJQaUUv5Wx57TF45djBTlbiY_CNSZWlBy49zWF-80bvPcbeAt8Ch-b6uHXH8adKw7bi0G8Buh66Z2wDXYsl1m3znG04tl0poMUL9irnI-e8qQBfsgtcKN6LesP-3MQ0zF5NLobC0Il8HAcKUxFt4d3oTBFUiKNKk9Oe8ofidhhTPJE5b7NORMGFH4UK5n-BSekUvRvmXPioDK1ieUqznub0qKFVSo5SLq6-7XfvX7MXVvlMb87zkn2_-Xy_-1ru777c7j7tS113OJU9GturltBCZVsBoFTLu8YiGMtRCYSKyKqqpkpwMOJQYVPXSvSVBXE49HjJrlbdxc-vmfIkB5c1ea8CxTnLCpEjAnZiQcWKLnZyTmTlmNyg0m8JXD60IY_y3IZ8aEOubSx3784v5sNA5vHqX_wL8HEFaDF6WjKQWTsKmoxLpCdponvixV_946Ew</recordid><startdate>20200225</startdate><enddate>20200225</enddate><creator>Kovačević, Anđelka B.</creator><creator>Müller, Rainer H.</creator><creator>Keck, Cornelia M.</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200225</creationdate><title>Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC)</title><author>Kovačević, Anđelka B. ; Müller, Rainer H. ; Keck, Cornelia M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-93df9a7e3f12f7511aa7086f31df03a5312eefa24e2501d5b23644a592f15bb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Hansen solubility parameter</topic><topic>Particle size</topic><topic>Polyhydroxy surfactant</topic><topic>Tacrolimus</topic><topic>Tailor-made lipid nanoparticle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kovačević, Anđelka B.</creatorcontrib><creatorcontrib>Müller, Rainer H.</creatorcontrib><creatorcontrib>Keck, Cornelia M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kovačević, Anđelka B.</au><au>Müller, Rainer H.</au><au>Keck, Cornelia M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC)</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2020-02-25</date><risdate>2020</risdate><volume>576</volume><spage>118918</spage><epage>118918</epage><pages>118918-118918</pages><artnum>118918</artnum><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted] Lipid nanoparticles are well-known nanocarriers for improved drug delivery. Their formulation development typically involves three formulations steps. In the first part a suitable lipid mixture which enables a high loading capacity and high encapsulation efficacy of the active needs to be identified (lipid screening). In the second step suitable stabilizers that enable the production of small-sized lipid nanoparticles with narrow size distribution and sufficient physical stability need to be identified (stabilizer screening, optimization of production parameters) and in the third step the biopharmaceutical efficacy needs to be evaluated. Based on the results obtained the formulations will require further optimization. The classical formulation development of lipid nanoparticles and especially the classical lipid screening is tedious. Therefore, in this study, a novel approach for the lipid screening that was based on the determination of the Hansen solubility parameters was evaluated and the results obtained were compared to the results from the classical model. Tacrolimus was used as a model drug. Results showed that both lipid screenings led to similar results, indicating that the new approach can be used for future developments. The optimized formulation was composed of a lipid matrix system that contained waxes, triglycerides and monoacylglycerols with various carbon chain lengths (C8, C10, C16, C18) and enabled an encapsulation efficiency of ~99%. The stabilizer screening showed that surfactants with high HLB values, lower molecular weight, and shorter alkyl chain length tended to form smaller particles with narrower size distribution and better physical stability. The most suitable surfactant was found to be a caprylyl/capryl glucoside (Plantacare® 810), a PEG-free stabilizer, that is extremely mild for atopic skin. It led to particle sizes of about 200 nm and a zeta potential well above |30| mV. The optimized formulation contained 0.1% tacrolimus and possessed good physical stability. In conclusion, an optimized method for the selection of lipids that results in a limited number of experiments could be established and tacrolimus loaded lipid nanoparticles with similar drug load as a marketed formulation was successfully developed in this study.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>31870954</pmid><doi>10.1016/j.ijpharm.2019.118918</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2020-02, Vol.576, p.118918-118918, Article 118918
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_2330331385
source ScienceDirect Freedom Collection
subjects Hansen solubility parameter
Particle size
Polyhydroxy surfactant
Tacrolimus
Tailor-made lipid nanoparticle
title Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T02%3A37%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Formulation%20development%20of%20lipid%20nanoparticles:%20Improved%20lipid%20screening%20and%20development%20of%20tacrolimus%20loaded%20nanostructured%20lipid%20carriers%20(NLC)&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Kova%C4%8Devi%C4%87,%20An%C4%91elka%20B.&rft.date=2020-02-25&rft.volume=576&rft.spage=118918&rft.epage=118918&rft.pages=118918-118918&rft.artnum=118918&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2019.118918&rft_dat=%3Cproquest_cross%3E2330331385%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c483t-93df9a7e3f12f7511aa7086f31df03a5312eefa24e2501d5b23644a592f15bb93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2330331385&rft_id=info:pmid/31870954&rfr_iscdi=true